Last reviewed · How we verify

Testosterone MD-Lotion

Acrux DDS Pty Ltd · Phase 3 active Small molecule

Testosterone MD-Lotion delivers testosterone through the skin to replace deficient levels in the body.

Testosterone MD-Lotion delivers testosterone through the skin to replace deficient levels in the body. Used for Hypogonadism in adult males.

At a glance

Generic nameTestosterone MD-Lotion
Also known asLY900011, Axiron
SponsorAcrux DDS Pty Ltd
Drug classAndrogen replacement therapy
ModalitySmall molecule
Therapeutic areaEndocrinology
PhasePhase 3

Mechanism of action

This topical lotion is designed to bypass the gastrointestinal tract and liver, allowing for direct absorption into the bloodstream via the skin, thereby restoring physiological levels of testosterone in hypogonadal men.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: